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Abstract
Hepatitis C virus (HCV) is a positive single-stranded RNA virus of enormous global health 
importance, with direct-acting antiviral therapies replacing an immunostimulatory interferon-
based regimen. The dynamics of HCV positive and negative-strand viral RNAs (vRNAs) under 
antiviral perturbations have not been studied at the single-cell level, leaving a gap in our 
understanding of antiviral kinetics and host-virus interactions. Here, we demonstrate quantitative 
imaging of HCV genomes in multiple infection models, and multiplexing of positive and negative 
strand vRNAs and host antiviral RNAs. We capture the varying kinetics with which antiviral drugs 
with different mechanisms of action clear HCV infection, finding the NS5A inhibitor daclatasvir 
to induce a rapid decline in negative-strand viral RNAs. We also find that the induction of host 
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antiviral genes upon interferon treatment is positively correlated with viral load in single cells. 
This study adds smFISH to the toolbox available for analyzing the treatment of RNA virus 
infections.
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HCV; single-molecule FISH; viral replication; host-virus interactions
Introduction
Hepatitis C virus (HCV) chronically infects the liver hepatocytes of around 150 million 
people worldwide, and is a major cause of end-stage liver disease (1). It is a single-stranded, 
positive sense RNA virus that uses its 9.6kb genome as a template for both translation of the 
viral polyprotein and transcription of the negative strand RNA intermediate (2). Historically, 
treatment options for HCV have consisted of immunity-enhancing interferon treatment, 
which is associated with low cure rates and harsh side effects (3). Recently, highly potent 
direct-acting antivirals (DAAs) have been developed against multiple viral targets and which 
have led to near complete HCV cure rates in single and combination therapy (4, 5). 
However, high costs and the demographics of infected patients have limited global access to 
these therapeutics, and the large population of infected but undiagnosed people means HCV 
will continue to be a public health concern (6, 7) on which further study is warranted.
Much work has been done to elucidate HCV replication dynamics and its relationship with 
the host cell response (6, 8–12), especially its induction of and evasion from hepatocyte 
innate immunity (13, 14). The regulatory mechanisms governing the levels of HCV viral 
RNA and proteins in individual infected cells are of particular interest, as HCV is generally 
non-cytopathic and infects a minority of hepatocytes in the liver (11, 15). To this end, 
temporal profiling of patient viral loads upon treatment have enabled the development of 
detailed quantitative models for viral replication and antiviral efficacy at the patient level 
(16–21), but these studies do not provide the resolution necessary to measure viral and host 
transcriptional dynamics in single cells, which would provide unique information about the 
mechanism of host cell responses to infection and to antiviral therapies. Single-cell analyses 
have been used recently to advance our understanding of biochemical variation (22–24) at 
both basal levels and under perturbations such as infection (25, 26), and single-molecule 
RNA imaging (smFISH) in particular has uncovered extensive inter-cell differences in 
mRNA expression that underlie phenotypic variation (24, 27–31).
Quantitative, single-molecule techniques have begun to advance viral RNA (vRNA) imaging 
as well, with some reports applying single-mRNA imaging to the study of single viral 
genomes in individual viral particles (32–34), and more recently to the analysis of HCV 
vRNA colocalization with components of infected cells (35). Here, we extend these studies 
by using simple, fluorescently labeled short oligos (27) to demonstrate sensitive, specific 
imaging of both HCV positive and negative strands and reporter viruses, compatible with 
multiple in vitro infection models and both standard and superresolution imaging. We detail 
the quantitative response of positive and negative strand vRNAs to multiple DAAs and 
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interferon (IFN) treatment at the single-cell level for the first time, observing distinct 
kinetics of viral inhibition induced by antivirals with differing mechanisms of action. 
Finally, by observing the heterogeneous response of individual HCV-infected cells to IFN 
treatment, we utilize simultaneous quantitative imaging of host mRNAs and vRNA to 
observe that HCV infection induces, and persists in spite of, strong upregulation of IFN-
stimulated gene expression. Overall, our results extend the toolbox of methods available for 
the analysis of RNA viral infection and treatment.
Materials and Methods
Cell culture
Huh-7 (36), Huh-7.5 (37), and a clone of Huh-7.5 stably integrating the NS3–4A activity 
reporter (38) were all propagated in a DMEM with L-glutamine (Cellgro)-based medium 
containing 100 U/mL penicillin, 100 µg/mL streptomycin (Cellgro), and 10% FBS 
(GIBCO). Primary human fetal liver cells (HFLCs) were isolated and plated as described 
(39). Cultures were maintained in Hepatocyte Defined Medium (HDM) (BD Biosciences) 
plus L-glutamine and antibiotics. Induced pluripotent stem cell (iPSC)-derived hepatocyte-
like cells (iHLCs) were derived and cultured as described (40, 41). For smFISH experiments, 
cultures were grown on 12 mm, circular, No. 1 glass coverslips (VWR) in 24-well plates. 
For Huh-7.5s, attachment to coverslips was improved by coating with rat tail collagen I (BD 
Biosciences) at 50 µg/mL in water for 1 hour at 37°C and then rinsing prior to seeding. 
HFLC attachment was enhanced by first coating with collagen and subsequently with poly-
L-lysine hydrobromide (Sigma) at 100 µg/mL for 45 minutes at room temperature and then 
rinsing prior to seeding. To put iHLCs on coverslips, they were treated with accutase 
(Millipore) for 15–20 minutes until they balled up. Gentle pipetting was performed to 
remove the cells, and they were then plated onto Matrigel-coated coverslips.
Hepatitis C virus infection, antiviral treatment, and interferon treatment
Hepatoma and iHLC infections were performed with a replication-competent Gaussia 
luciferase-expressing reporter virus based on the efficient Jc1 HCV construct (Jc1-Gluc) 
(42); stocks of this reporter were obtained as described (43). HFLC infections were 
performed either with this Jc1 reporter or with an adapted HCV called J6/JFH Clone 2 (44). 
Titration on naïve Huh-7.5s was used to determine 50% tissue culture infectious dose 
(TCID50) of stocks of these strains of HCV. For infection experiments, we employed three 
standard models of HCV infection: the Huh-7.5 hepatoma cell line (as well as the associated 
Huh-7 cell line and the clone of Huh-7.5 stably expressing the NS3–4A activity reporter as 
described below) (45), primary human fetal hepatocytes (39), and induced pluripotent stem 
cell-derived hepatocyte-like cells (40). Stocks were diluted in the appropriate culture 
medium to make an inoculum with final titer typically in the 105–106 TCID50/mL range 
(MOI ranging from ~0.2-2). Cultures to be infected were incubated in inoculum for varying 
durations depending on the experiment. Subsequently, medium was typically changed every 
24–48 hours unless otherwise noted, and cultures were washed with culture medium three 
times between medium changes. To demonstrate that smFISH imaging of HCV genomes is 
replication-dependent, the HCV non-structural protein 5B (NS5B) polymerase inhibitor 2’-
C-methyladenosine (2’CMA), with EC50 = 27 nM (45), was used to supplement both the 
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inoculum and subsequent fresh medium at a concentration of 80*EC50 (final 0.1% DMSO) 
and compared to a DMSO-only control. For antiviral experiments, human interferon β (IFN-
β) (Calbiochem, used at 100 U/mL for comparative antiviral experiments, and 10 U/mL for 
host response experiments), sofosbuvir (10 uM; EC50 ~ 20 nM(46)), daclatasvir (1 nM; 
EC50 ~ 20 pM(47)), and simeprevir (400 nM; EC50 ~ 10 nM(48)) were used to treat cells at 
the above concentrations (chosen as 10*EC90 based) in a final concentration of 0.1% 
DMSO, at indicated time points either before or after infection as described.
Single-molecule RNA FISH (smFISH)
smFISH on culture samples is performed as described in detail (27). All protocols are also 
available online at http://www.singlemoleculefish.com. Briefly, culture samples on 
coverslips are fixed in 4% w/v paraformaldehyde (Electron Microscopy Sciences) in PBS for 
10 minutes. After washing with PBS, samples can be maintained in PBS for at least one 
week at 4°C. Six hours prior to hybridization with probes, samples are permeabilized by 
placing in 70% EtOH in water at 4°C. Coverslips are incubated in hybridization buffer 
containing a probe set targeting the RNA species of interest (BioSearch Technologies; http://
www.singlemoleculefish.com; sequences in sets shown here are provided in Supplemental 
Information which are probe sets of 48 probes targeting the Gaussia-luciferase-expressing 
HCV reporter described above; we have successfully quantified HCV with various probe 
sets (Supplementary Information) each probe of which is coupled to desired fluorescent 
molecule (typically Alexa594 or Cy5). Multiple probe sets coupled to spectrally distinct 
probe sets can be hybridized to sample simultaneous for multiplexed imaging. Finally, 
samples are washed, during which time fluorescent molecules targeting antigens of interest 
or immunofluorescence antibodies can be incorporated as described (27), and subsequently 
mounted for imaging. In this study, endoplasmic reticulum staining was performed using the 
ER-ID Green assay kit (Enzo Life Sciences), and HCV non-structural protein 5A (NS5A) 
immunostaining was performed using mouse anti-NS5A (9E10) and goat anti-mouse Alexa 
Fluor 594 (Invitrogen).
Microscopy and image analysis
Standard epifluorescence microscopy can ascertain smFISH spots as described (27). All 
images were taken with a Nikon Ti-E inverted fluorescence microscope equipped with a 
100X oil-immersion objective and a Photometrics Pixis 1024 CCD camera using 
MetaMorph software (Molecular Devices, Downington, PA). Z-stacks were obtained as 
described (27); typically, 20–30 planes separated by 0.4 µm was sufficient to 
comprehensively cover the target cells. Images presented as slices from the Z-stack or 
maximum intensity projections as described. Images were analyzed to extract data we show 
using custom software written in MATLAB (MathWorks), which can identify spots on 
individual channels, assess co-localization, and quantify spots. Briefly, a Laplacian of 
Gaussian (LoG) filter is used to filter out slowly-varying background noise and spots outside 
of the size and shape range for fluorescent foci (e.g. autofluorescent cellular components), 
and spot counts are determined by thresholding the filtered image, where the threshold is 
determined empirically by minimizing the sensitivity of spot counts to changes in threshold. 
Quantification has an upper-bound for each cell that depends on cell volume (height and 
cross-section), subcellular distribution of target RNA, quality of imaging, and signal-to-
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noise ratio. At later time-points post infection (~48 hours), the number of positive strands as 
visualized using an Alexa594 fluorophore probe set typically was deemed too large to be 
counted computationally without significant error in a small portion of the cells. For these 
cells, an estimate was obtained by integrating the fluorescence intensity in a sum projection 
of the Z-stack for the cell and subtracting the local background, and comparing this quantity 
with that of countable cells to extrapolate an estimate (49). In order to obtain spot intensity 
distributions, we used custom-written MATLAB software to reduce the stacked images to 
two-dimensional images by maximum projection, and fitted the fluorescent spots to a 2D 
Gaussian as the model for the point spread function. Single transcript intensity was defined 
as the integrated intensity of the spot using the two-dimensional Gaussian mask algorithm. 
Structured illumination microscopy (SIM) images were performed using a DeltaVisionOMX 
3D Structured Illumination Microscope (Applied Precision, Issaquah, USA). Solid state 
lasers (405, 488, 593 nm) provided wide-field illumination and multi-channel images were 
captured simultaneously using 3 Photometrics Cascade (Photometrics, Tucson, USA) back-
illuminated EM-CCD cameras. All data capture used an Olympus UPlanSApo 100× 1.4NA 
oil objective and standard excitation and emission filter sets. 3D–SIM images were sectioned 
using a 125 nm Z-step size. Raw 3-phase images were processed and reconstructed using 
softWoRx (Applied Precision) as previously described (50). Confocal microscopy images 
were taken using a Zeiss Axiovert Microscope (Carl Zeiss, Oberkochen, Germany) and a 
Perkin Elmer Ultraview Spinning Disk Confocal. Solid state lasers provided wide-field 
illumination and multi-channel images were captured using Hammamatsu ORCA-ER CCD 
camera (Bridgewater, NJ). All data capture used a Zeiss ApoChromAT 100× 1.4NA oil 
objective and standard excitation and emission filter sets. Raw images were processed and 
reconstructed using Volocity software (Perkin Elmer, Waltham, MA).
HCV non-structural protein 3–4A (NS3–4A) activity reporter
As previously described (38), we developed a real-time fluorescence reporter of HCV 
infection based on monitoring NS3–4A protease activity. A clone of Huh-7.5 stably 
expressing the RFP-NLS-IPS was used to determine the correlation between smFISH 
imaging of HCV genomes and NS3–4A protease activity.
Strand specific qPCR of HCV RNA
Non-infectious positive strand standards were constructed by digesting a plasmid containing 
J6/JFH1 “Clone 2” virus (51) with SacI (New England Biolabs) and religating the backbone. 
After XbaI (New England Biolabs) digestion, this DNA was used in a T7 transcription 
reaction to yield a 3516nt RNA standard with intact 5’ and 3’ ends. For minus strand 
standard synthesis, we employed an overlap PCR approach to flip the orientation of the 
positive strand standard while preserving the appropriate ends. Generated RNA stocks of 
both strands were equilibrated via nanodrop to a calculated concentration of 1010 copies/µl. 
Standard curves were generated by serially diluting the RNA standards in the presence of 
fixed 50ng amounts of total RNA from uninfected Huh-7.5 cells. For qPCR of unknown 
samples, RNA was isolated using the RNeasy Plus Mini kit (Qiagen) from infected Huh-7.5 
cells. Approx 50ng of total RNA was then used for PolyAdenylation using E. coli PolyA 
Polymerase (New England Biolabs) using 1mM ATP, 3U E-PAP and 7.5U RNAsin Plus 
RNAse inhibitor (Promega, Madison, WS) in a 5ul total reaction volume, and incubated for 
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10 minutes at 37°C followed by 20 minutes at 65°C to inactivate the enzyme. The resulting 
RNA underwent reverse transcription using Superscript III (Life Technologies): to the 5µl of 
poly-A tailed RNA, 2.5 pmol of tagged RT primer (5’-
GAATCGAGCACCAGTTACGCATGCCGAGGTCGACTTCCTAGATTTTTTTTTTTTTTT
TTTTVN −3’) was added along with 0.5µl of 10mM dNTPs, and incubated at 65°C for 5 
minutes before placing on ice. To this mixture the RT mix was added per reaction consisting 
of 1× RT Buffer, 50mM DTT, 2.5U RNAsin Plus RNAse inhibitor and 100U Superscript III, 
to a final RT reaction volume of 10µl. Samples were incubated at 55°C for 10 minutes, 60°C 
for 50 minutes and 85°C for 5 minutes and held at 4°C. Inferred from input RNA amounts, 
approximately 2ng of the resulting cDNA was used per subsequent qPCR reaction using 2× 
FastStart SYBRGreen qPCR mix (Roche) following the manufacturer’s instructions and 
using 2.5 pmol primer for the tag sequence (GAATCGAGCACCAGTTACGCATG) and 
either the positive strand primer (CTGGTCTCTCTGCAGATCATGT) or the negative strand 
primer (CTGCGTGAAGACAGTAGTTCCTCA) also at 2.5 pmol. For convenience in some 
experiments, we adapted the miScript RT kit (Qiagen) that employs a polyA-tailing and RT 
step with the above RT primer in a single reaction, to produce the necessary input for 
subsequent qPCR using HCV specific primers and the tag primer. qPCR was carried out 
using iQ5 thermal cyclers (BioRad) using the following cycling parameters: 95°C for 
10minutes, 40 cycles of [95°C for 15s, 58°C for 15s, 72°C for 20s collecting fluorescence], 
95°C for 2 minutes, 55°C for 2 minutes followed by fluorescence measurement for each 
0.5°C interval increase to 95°C for the generation of melt curves. Non-strand specific qPCR 
for HCV RNA was carried out using MultiCode-RTx technology (Eragen Biosciences) as 
described previously (52).
Statistical analysis
Error bars plotted as standard deviation (σ) or as standard error of the mean (SEM) as noted. 
Statistical analysis performed as described – two-tailed t test, one-way ANOVA with 
Tukey’s post-test, linear regression, and F test for determining positivity of slope performed 
using GraphPad Prism 5 (GraphPad Software). Pearson correlation coefficients obtained 
using MATLAB (The MathWorks).
Results
Specific and sensitive single-molecule imaging of genomic vRNA
We first tested our ability to perform mRNA smFISH (27) on HCV, by developing 
fluorophore-tagged, short oligonucleotide probe sets for HCV RNA, which localize to 
produce diffraction-limited spots under standard epifluorescence microscopy after being 
delivered to fixed and permeabilized infected cells (Fig. 1A). To test the specificity of the 
method, we performed single-molecule vRNA imaging on HCV-infected Huh-7.5 cells (37, 
53) using a Cy5 probe set targeting the 5’ half of the strand, and an Alexa594 probe set 
targeting the 3’ half, for both positive (+) and negative (−) strands. While smFISH 
performed on uninfected hepatoma cultures (Fig. S1A) or infected cultures without probes 
(Fig. S1B) both revealed no spots, infected cultures imaged simultaneously with both Cy5 
and Alexa594 probe sets for either the positive or negative strand revealed diffraction-
limited spots in both channels (Fig. 1B), with co-localization frequencies (>80%) (Fig. 1B) 
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similar to what has been observed for mRNAs (27). In order to assess whether vRNA spots 
represent single genomic strands, we employed a method previously reported for single 
molecule imaging whereby we integrated total spot fluorescence for many spots of both 
positive and negative-strand vRNA to determine whether the spot intensity was unimodal 
(54), which would suggest spots are mostly single genomes. We found that the distribution 
of spot intensities was unimodal (Fig. 1C) and close to lognormal, suggesting that most 
spots represent single-molecule events, as previously seen with this technique (55, 56), 
although the brightest data points within the distribution (at the far right of the X axis) may 
represent foci of viral transcription. Because HCV positive- and negative-stranded vRNAs 
can exist as duplexed dsRNA, which may not be accessible to our ssDNA probes, we 
examined the ability of smFISH to capture duplexed vRNAs by transfecting pre-complexed 
HCV dsRNA as a positive control and quickly fixing and imaging samples. We found that 
duplexed dsRNA is still detected as colocalized positive- and negative-strand vRNA, likely 
due to the denaturing hybridization conditions, suggesting that the smFISH protocol allows 
for probe binding to dsRNA (Fig. S1L).
Throughout the period we sampled, the number of HCV RNA spots increased with time post 
infection (Fig. 1D), and was greatly reduced in the presence of an antiviral compound, the 
HCV non-structural protein 5B (NS5B) polymerase inhibitor 2’-C-methyladenosine 
(2’CMA) (Fig. 1E). We also compared the results obtained using vRNA smFISH to those 
using a highly sensitive, single-cell fluorescent reporter of HCV infection that discriminates 
infected from uninfected cells based on the protease activity of HCV non-structural protein 
3–4A (NS3–4A) (38). In this assay, in the absence of NS3–4A activity (reporter negative), 
fluorescence is localized to the cytosol, whereas nuclear fluorescence is induced in infected 
cells that exhibit active NS3–4A (reporter positive), which cleaves the reporter to expose a 
nuclear localization signal, resulting in nuclear transport of the fluorescent tag. By 
combining these two methods, we observed significantly more smFISH spots present in 
reporter positive than reporter negative cells (Fig. 1F), providing an independent single-cell 
measure of infection to correlate with our vRNA imaging technique. Amongst the reporter 
negative cells, a range of smFISH spot counts were detected, suggesting that vRNA smFISH 
is even more sensitive than an enzymatic viral protein-driven reporter, and thus may detect 
infection at a lower viral load.
Since smFISH maintains spatial information and is compatible with most fluorescent 
imaging modalities and co-stains, we next tested whether we could perform smFISH of 
HCV using super-resolution three-dimensional structured illumination microscopy (3D–
SIM) (57). We observed co-localization of HCV positive strands jointly with the 
endoplasmic reticulum (ER), with which viral replication complexes associate (Fig. S1C) 
(58, 59), and also with HCV non-structural protein 5A (NS5A) (Fig. S1D). We also sought 
to extend the utility of our method by testing it using authentic host cells, given that HCV 
host-virus interactions are more relevant when studied in non-transformed cell lines. To this 
end, we attempted smFISH using two primary hepatocyte models of HCV infection – 
induced pluripotent stem cell (iPS)-derived hepatocyte-like cells (iHLCs) (60) and primary 
human fetal liver cells (HFLCs) (39). Infected iHLCs (Fig. S1E) and HFLCs (Fig. S1G), but 
neither uninfected iHLCs (Fig. S1F) nor uninfected HFLCs (Fig. S1H) demonstrate positive 
strand vRNA smFISH spots, with fewer strands detected in the presence of 2’CMA (Fig. 
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S1I). While only 40% of HFLCs were reporter positive in replicate samples, at least one 
viral genome was detected in 93% of HFLCs, suggesting improved sensitivity of the 
smFISH method (Fig. S1J). Because virus-infected cells can undergo coinfection or 
superinfection, we wanted to determine if our smFISH method could facilitate orthogonal 
imaging of multiple viral variants. To do this, we synthesized a fluorescently-tagged set of 
probes complementary to the genomic sequence of a tagRFP reporter inserted into a reporter 
HCV genome, and demonstrated specific targeting of this exogenous viral sequence (Fig. 
S1K) as well as targeting of an exogenous luciferase viral reporter (data not shown).
Single-cell, multiplexed quantification of viral positive and negative strands enable studies 
of the viral life cycle
Having established smFISH as a specific and sensitive method to visualize HCV infection in 
a range of hepatic cells, we next applied the technique to study viral replication dynamics by 
simultaneously enumerating positive and negative strand spots within individual cells. 
Huh-7.5 cells were infected with HCV and fixed at various hours post infection (hpi) (Fig. 
2A). Multiplexed imaging was performed using two spectrally distinct probe sets, each 
targeting a different vRNA strand (Fig. 2A). At each time point, the resulting images (Fig. 
2B) yielded a single-cell joint distribution of positive and negative strand spot counts that 
evolved over time. We averaged positive and negative strand data over many cells (Fig. 2C) 
to measure how average negative-to-positive strand ratios (NPSR) vary over time (Fig. 2C, 
inset). We also present single-cell data for viral RNAs and NPSR dependence on infection 
load at 48 hpi (Fig. 2D). While significant inter-cell heterogeneity was detected, positive and 
negative strand vRNAs were correlated at the single-cell level. Because the Jc1-Gluc virus is 
replication-competent, the low-strand spot cells at late timepoints may represent cells newly 
infected by virus produced in culture. Infected cells also cluster bimodally into 
subpopulations bearing low or high strand counts (Fig. S2).
In order to cross-validate our vRNA measurements with an independent assay, we developed 
a new PCR assay that improves our capacity to discriminate between positive and negative 
strand vRNAs, since the application of previously published methods yield NPSR values for 
HCV that range widely from 1:10 to 1:1000, and these readings have been confounded by 
both interference from the opposite strand, and detection of incomplete vRNAs (61–66). In 
this updated assay, total RNA is poly-A tailed, after which a tag oligo-dT anchored primer is 
used to reverse transcribe from the nascent tail (Fig. S3A); the resulting complementary 
DNA (cDNA) is then used for qPCR, employing a primer for the tag sequence and an HCV-
specific primer for the 3’ end of the target vRNA. This assay offers two main updates 
relative to previously employed tagged assays (63–65), in that strand specificity is 
introduced at the PCR stage, and amplicons are generated that straddle the 3’ ends of 
completed positive and negative strand products of the viral polymerase. Using standards for 
both strands individually, we confirmed that the assay is sensitive over 8 logs for either 
strand (Fig. S3B). In addition, we used mixtures of positive and negative strand standards to 
determine that both strands could be detected unambiguously within a large range; single 
negative strands could be reliably detected in the presence of 103 positive strands, while 
positive strands could be detected in up to 100-fold excess of negative strands (Fig. S3C). 
Using PAqPCR to measure vRNA side-by-side with smFISH on replicate samples, we found 
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that both assays yielded a similar fold change in positive or negative strand vRNA between 
two time points post infection (Fig. S3D, Fig. S3E), suggesting that smFISH can be 
considered quantitative when used to enumerate both positive and negative strands.
smFISH elucidates the single-cell response of infected cells to antiviral drugs
After validating the strand-specific and quantitative data gleaned via smFISH of vRNA, we 
sought to determine whether this same technique could be used to detect differing antiviral 
signatures. To this end, we investigated the impacts of four compounds that function via 
distinct mechanisms of action: IFNβ, a virus-induced host signaling protein that induces 
interferon-stimulated genes (ISGs) with antiviral activity; and three direct-acting antivirals: 
sofosbuvir (SOF), a nucleotide analog and inhibitor of the HCV polymerase NS5B; 
daclatasvir (DCV), an inhibitor of the multifunctional HCV protein NS5A; and simeprevir 
(SIM), an inhibitor of the HCV protease NS3–4A. We infected Huh-7.5 cells with HCV for 
4 hours, and at 24 hpi, cultures were treated with each of the compounds and fixed at 6, 12, 
16, and 24 hours post dosing (hpd) for smFISH analysis (Fig. 3A). The single-cell bivariate 
data for positive and negative strands (Fig. 3B) reveal varied response characteristics 
between drug treatments, and in particular the cellular response to IFN treatment appears 
more heterogeneous in its strand skew than the response to DAA treatment.
To enable the drawing of more specific inferences regarding drug effects and mechanisms, 
we aggregated the data and normalized the responses relative to the DMSO control (Fig. 3C) 
to yield a strand-specific viral decay time course for each treatment. All 4 treatments 
produced a noticeable impact on viral RNAs by 24 hpd; however, the kinetics of viral decay 
varied significantly between groups. Response to IFN was delayed relative to the DAA 
treatments, and among the DAAs, patterns of strand decay varied greatly, with concordant 
decay between positive and negative strands upon SOF treatment, but rapid, selective 
negative strand depletion upon DCV treatment.
Single-cell, multiplexed imaging of viral strands and host genes track host-virus 
interactions
Since interferon-mediated clearance depends on host cell responses, and our single-cell 
observations revealed cell-to-cell variability in viral clearance upon interferon treatment, we 
sought to look more directly at this phenomenon by harnessing the capacity of smFISH to 
simultaneously measure viral RNA and host mRNA in individual host cells (Fig. 4A). IFN 
stimulation initiates a JAK/STAT signaling cascade that culminates in the induction of 
antiviral interferon-stimulated genes (ISGs) (67–69). We developed smFISH probe sets that 
target mRNA transcripts for two prototypical ISGs with anti-HCV activity (70): EIF2AK2/
PKR, which phosphorylates EIF2α to reduce host translation and inhibit HCV (71, 72), and 
ISG15, a multifunctional protein which “ISGylates” proteins for targeted degradation (73). 
As a positive control, uninfected Huh-7.5 cells treated with IFN-β for 6, 12, or 24 hours 
were fixed and assayed by smFISH. As expected, the baseline EIF2AK2 and ISG15 
transcript levels were visualized as diffraction-limited spots that rapidly increased in number 
upon administration of IFN-β (Fig. S4A–B, Fig. 4D), and reached a stable plateau for at 
least 6 to 24 h (Fig. S4B). Notably, despite uniform administration of IFN-β, ISG expression 
varied significantly between individual cells in the treated population. In order to determine 
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whether the induction of ISG expression upon IFN treatment correlated with vRNA levels, 
infected Huh-7.5 cells were fixed for multiplexed imaging of HCV vRNA with either ISG15 
or EIF2AK2, before or after a 12 h exposure to IFN-β (Fig. 4B). In the absence of IFN-β, 
hepatoma cells did not upregulate ISG mRNAs upon infection (Fig. 4D), and no correlation 
was observed between ISG mRNA and HCV vRNA levels (Fig. 4D, grey). This observation 
is consistent with reports of a defective RIG-I sensing of HCV vRNA in Huh-7.5s (74). 
However, after treatment with exogenous IFN-β, while HCV strand counts were not 
significantly reduced (Fig. S4C), the levels of both ISG mRNAs positively correlated with 
HCV infection load (Fig. 4C–D, red, Fig. S4D), and ISG levels observed in poorly infected 
cells were similar to those detected in uninfected controls (Fig. 4D, red). To better visualize 
this trend, we binned individual cells into groups with “low” and “high” levels of infection 
(Fig. S4E), and observed that only highly infected cells harbor significantly more ISG 
mRNAs than uninfected controls (Fig. S4F). These data suggest that although HCV can 
subvert hepatocyte innate immunity in multiple ways (75–77), viral products stimulate, 
rather than repress, ISG transcription upon IFN treatment.
Discussion
In this study, we demonstrated sensitive, specific, and quantitative imaging of HCV and 
other viral RNAs (tagRFP reporter sequence, Fig. S1K; DENV-2, data not shown). We 
demonstrated multiplexing of positive and negative vRNA strands, vRNA with host ER and 
viral proteins, and vRNA with host cell mRNAs (Fig. S1C–D; Fig. 2–4). Furthermore, we 
highlighted the applicability of this approach to primary cell infection models (Fig. S1E–H) 
that more closely recapitulate physiological infection of quiescent cells with normal host 
gene expression and intact innate immune signaling (74, 78, 79). While a previous smFISH 
analysis of HCV (35) focused on colocalization of vRNAs with ribosomes and viral 
proteins, here we extend the application of vRNA smFISH to the study of host-pathogen 
interactions downstream of IFN signaling, and viral clearance upon antiviral treatment.
Using our specific and quantitative approach, verified using our novel PCR-based bulk assay 
(Fig. S2), we demonstrate that while the general understanding has been that positive strands 
greatly outnumber negative strands in ssRNA(+) viruses (80, 81), we find that this ratio 
varies significantly with time. We observed that the mean single-cell NPSR starts low at 4 
hpi,consistent with early virion unpacking and minimal replication, and in Huh-7.5 cells this 
ratio increases, followed by possible tapering thereafter (Fig. 2C, Inset). The data at 48 hpi 
shows that NPSR appears negatively correlated with positive strand spots at the single-cell 
level until approximately ~200 positive-strand spots, with a more stable distribution above 
this number (Fig. 2D, Inset), mirroring the population-scale NPSR trends. One hypothesis is 
that negative strand production may peak at lower single-cell viral loads in order to produce 
the templates that enable subsequent rapid replication of positive strands, followed by a 
transition from transcription-dominant to translation-dominant production of new viral 
species from positive strand vRNAs. Since the Jc1-Gluc virus produced in culture can 
reinfect Huh-7.5 cells, it is possible that cells with low positive-strand spot counts at late 
timepoints like 48 hpi represent secondary infection events from culture-derived virus. In 
this case, the more stable NPSR at higher positive-strand counts could indicate the greater 
stability of this ratio at longer times post-infection in a given cell.
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The high-resolution strand-specific data enabled by smFISH also provides interesting 
information relating to HCV antivirals and their mechanisms of action (Fig. 3B–C) (18, 21, 
82). The delayed, robust response to IFN, for example, may be due to the time required for 
cellular antiviral proteins to be induced, transcribed, and translated upon IFN treatment. 
Furthermore, while treatment with the polymerase inhibitor, SOF, led to a balanced decay of 
both positive and negative strands, by blocking template transcription from both positive and 
negative strand vRNAs, the NS5A inhibitor DCV caused a skewed depletion of negative 
strand vRNAs with a shorter-than-expected half-life of 3 hours (17, 82–84). Indeed, across 
all treatments, very few cells exhibited a strand skew that favored negative strand vRNAs. 
This finding may suggest the negative strand is intrinsically less stable, a hypothesis that is 
consistent with previous reports suggesting the negative strand is less stable due to fewer 
interactions with miR-122 (11, 85) or other factors. However, since both NS5A inhibitors 
and HCV protease inhibitors have been shown to inhibit viral assembly and/or release (17, 
86), the measured positive strand decline with these drugs (DCV and SIM) may be slowed 
somewhat by retention of otherwise-exported positive strand vRNAs.
The single cell data collected will likely be compatible with integration into existing 
computational and treatment (16, 18, 84, 87, 88), where the rates of strand-specific vRNA 
decay can shed light on which components of the viral life cycle are affected by 
therapeutics. For example, we are intrigued by the rapid effects of DCV on HCV negative 
strand vRNA, which had not been identified in a previous non-strand specific analysis of 
DCV temporal effects (17). Considering this result, and based on a sensitivity analysis 
performed in a recent computational HCV model (84), it would be interesting to explore 
whether inhibitory effects of DCV on NS5A–associated replication complexes serve as 
important drivers of rapid negative strand decline, as NS5A relocalization from RCs (89) 
may sensitize negative strands to rapid degradation. While the DAAs employed here were 
selected based on their known viral targets, future smFISH-mediated studies of post-
treatment viral kinetics may provide insights into antiviral mechanism of action by matching 
strand-specific vRNA kinetic profiles to drugs with known mechanism, and offer a 
framework for the comparison of novel drugs or drug combinations.
Compared to the DAAs, IFN produces a more variable response to HCV across a population 
of individual cells, which we aimed to dissect in more detail by simultaneously measuring 
vRNAs and host antiviral mRNAs induced by IFN treatment. HCV possesses numerous 
ways to evade hepatocyte innate immunity, both upstream and downstream of cell-intrinsic 
Type I IFN production, such as the cleavage of MAVS and TRIF by the NS3–4A protease, 
induction of SOCS3 to block JAK/STAT signaling by HCV Core, and induction of PP2A 
and PKR which also block ISG transcription and translation, respectively (75, 90, 91). 
Because HCV can dampen the IFN cascade at numerous stages, which may confound 
interpretation of its inhibitory effect, we used smFISH to specifically look at whether HCV 
prevented accumulation of ISG transcripts soon after IFN treatment. In stark contrast, we 
found that after treatment with exogenous IFN-β, ISG mRNAs positively correlated with 
HCV infection load (Fig. 4C–D, Fig. S4D). While the innate immune axis in Huh-7.5 cells 
is known to be compromised in RIG-I signaling (74), our analysis takes place downstream of 
IFN-β signaling and corroborates recent results in treatment-naïve, HCV-infected patient 
liver tissue, where hepatocytes positive for HCV vRNA by bDNA-FISH also contained 
Ramanan et al. Page 11
Virology. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
significantly more IFI27 mRNA (92). It is possible that within our experimental timeframe, 
the effect of HCV upregulation of SOCS3 and other inhibitors of JAK/STAT signaling is not 
yet evident, but also highlights the fact that high ISG transcript levels do not correlate with 
clearing infection, even in patients treated with IFN (93). Indeed, the post-transcriptional 
blockage of ISG effectors by HCV, for example, via induction of PKR (71), may inhibit 
antiviral responses even in the presence of upregulated ISG transcription.
In summary, this study provides evidence for the numerous ways in which quantitative 
vRNA imaging can boost our understanding of HCV, and RNA viruses more generally, by 
providing single-cell traces of responses to antiviral drugs, and allowing for single-cell 
correlative measures of host and viral responses. Our inexpensive smFISH technique for 
quantitating vRNA functions at an efficiency that is on par with a proprietary branched DNA 
amplification method recently used to detect single HCV vRNAs (35), and can be integrated 
with rapid-staining techniques for increased throughput (94). This toolbox can be extended 
by offering simultaneous single-cell protein and RNA-level imaging when combined with 
fluorescent reporter viruses and integration with flow-based quantification (95, 96), or by 
simultaneous monitoring of two viral mutants with appropriate reporter sequences to study 
questions of drug resistance and superinfection (97).
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Highlights
• A single-genome imaging system for hepatitis C virus infection is 
demonstrated.
• Antiviral drugs clear positive and negative HCV strands with different 
kinetics.
• HCV NS5A inhibition results in a rapid decline in negative-strand HCV RNA.
• Single-cell viral genome number correlates with interferon-stimulated gene 
induction.
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Figure 1. Specific and sensitive imaging of individual molecules of genomic viral RNA (vRNA)
(A) Schematic illustration of single-molecule RNA FISH (smFISH) method (27). A set of 48 
DNA FISH probes (20 nucleotides/probe) that are each end-labeled with one fluorophore 
(red) and that are complementary to non-overlapping portions of the target RNA (Left) are 
introduced to fixed and permeabilized cells. Hybridization of probes to the target RNA 
(Center) produces sufficient local fluorescence for the RNA molecule to be visualized as a 
diffraction-limited spot using standard epifluorescence microscopy (Right); spots are 
detected only once a minimum number of probes (typically ~20 (27)) bind the target. (B) 
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Co-localization of diffraction-limited spots in infected Huh-7.5 hepatoma cultures (16 hours 
post infection) was detected by simultaneously introducing two spectrally-distinct probe sets 
(coupled to Cy5 and Alexa594 respectively) targeting different portions of the same genomic 
vRNA strand. Typical images of positive (Left, Z-stack projection, scale bar ≈ 5.0 µm; Inset, 
~2× zoom) and negative (Center, Z-stack projection, scale bar ≈ 4.0 µm; Inset, ~2× zoom) 
strand spots shown. Percentage of Cy5 and Alexa594 spots that co-localize with the other 
channel are shown for both strands (Right). (C) The integration of the range of spot 
intensities observed are presented as a histogram of the distribution of intensities for spots 
measured 24 hours post infection (hpi) for both strands. (D) Number of positive strand spots 
in individual cells at 12 and 24 hpi (red line = mean). Difference was statistically significant: 
****p < 0.0001 (two-tailed t test). (E) Number of positive strand spots in individual cells in 
DMSO or the HCV NS5B polymerase inhibitor 2’CMA at 24 hpi (red line = mean). 
Difference was statistically significant: ****p < 0.0001 (two-tailed t test). (F) NS3-4A 
activity reporter (38) deems cells infected based on nuclear fluorescence and uninfected 
based on cytosolic fluorescence. The Huh-7.5 Clone 8 line which carries this reporter stably 
was used to compare NS3-4A imaging with smFISH. Sample images from the same field of 
view for both NS3-4A reporter (Left, scale bar ≈ 18.5 µm) and smFISH (Center, ≈ 18.5 µm) 
are shown. Number of positive strand spots in reporter negative or reporter positive cells 24 
hpi are provided (red line = mean) (Right). ****p < 0.0001 (two-tailed t test).
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Figure 2. Multiplexed quantification of positive and negative viral strands in individual cells
(A) Schematic illustration of experiment. Huh-7.5 hepatoma cells were inoculated with 
HCV for 4 hours, and then fixed (triangles) for smFISH at various times thereafter (Left). 
Multiplexed imaging was performed by simultaneously employing an Alexa594 probe set 
for the positive strand and a Cy5 probe set for the negative strand (Right). (B) Sample 
images at 4 (Left, Z-stack projection, scale bar ≈ 7.0 µm) and 48 hpi (Right, Z-stack 
projection, scale bar ≈ 6.0 µm). (C) The average number of positive and negative strand 
spots observed per cell are plotted for each timepoint (4 hpi: n = 70 cells; 12 hpi: n = 44 
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cells; 24 hpi: n = 67 cells; 48 hpi: n = 63 cells). Data plotted as mean ± standard deviation 
The average single cell negative:positive strand ratio (NPSR) at each timepoint are plotted as 
mean ± standard deviation (Inset). (D) The absolute number of positive and negative strand 
spots per indivudal cell at 48 hpi are presented as a scatter plot (n = 63) (Pearson correlation 
coefficient ρ = 0.86). Axes are split into two linear segments each: 0–100, 100–600. After 
binning cells by intervals of 50 positive strand spots, the average single-cell NPSR was 
calculated for each bin, and is plotted as mean ± standard deviation (Inset).
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Figure 3. Kinetics of vRNA expression during antiviral drug treatment
(A) Schematic illustration of experiment. Huh-7.5 hepatoma cells were inoculated with 
HCV for 4 hours, and then drug treatment was started at 24 hpi. Cells were fixed for staining 
(triangles) at various = hpi – 24) (Left). Multiplexed imaging was performed by 
simultaneously employing an Alexa594 probe set for the positive strand and a Cy5 probe set 
for the negative strand (Right). (B) Scatter plots of positive and negative strand spot counts 
per cell, over time (6, 12, 16, and 24 hpd) during treatment with each antiviral compound 
(IFN-beta, SOF, SIM, DCV), or DMSO control. Linear best-fit lines for each condition are 
included to aid in visualization of HCV viral strand skew in response to each antiviral. (C) 
The average number of positive or negative strand spots per cell were calculated at each 
timepoint, and the resulting values for each antiviral treatment were normalized relative to 
the number of positive and negative strands in DMSO controls (n = 35–85 per data point), to 
give a population-wide perspective of the impact of drug treatment on each sense of viral 
RNA. Data are plotted as mean ± SEM.
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Figure 4. Multiplexed quantification of viral positive strands and host mRNA transcripts in 
individual cells
(A) Schematic illustration of concept. The presence of correlated infection and host gene 
expression at the single-cell level (Top) can be identified using multiplexed smFISH to plot 
data that yields a single-cell joint distribution for a vRNA and host gene of interest (Bottom 
Left). By analyzing the relationship between vRNA levels and host gene levels on a per-cell 
basis, hypotheses about host gene regulation of vRNAs, or vice versa, can be generated and 
tested. For example, if host gene distribution is unperturbed upon infection, but vRNA levels 
are higher in cells with more host gene spots, pathways mediated by the assayed host gene 
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may boost viral replication (Bottom Right). (B) Schematic illustrating the experiment, 
designed to ascertain the presence or absence of a relationship between HCV infection and 
interferon-stimulated gene (ISG) expression by dosing with the Type I interferon (IFN), 
IFN-β. Multiplexed smFISH for HCV positive strand spots and either EIF2AK2 or ISG15 
spots is performed on infected (48 hpi) or uninfected cells before or after dosing with 10 
U/mL IFN-β for 12 hours. (C) Multiplexed images of HCV positive strand spots (Left), and 
ISG15 mRNA (Right) in the same field of view (scale bar ≈ 17.0 µm), 12 hours post dosing 
of IFN-β. (D) Scatter data plots the joint distribution for the number of two different ISG 
mRNA transcript spots (EIF2AK2, left and ISG15, right) versus positive HCV strand spots 
in individual, infected cells. In each plot, controls are presented on the left side of the X axis 
(HCV-), such that each point represents the number of ISG mRNA spots in individual, 
uninfected cells. The left-to-right green gradient tracks the increasing viral load within 
infected cells, based on the number of HCV positive strand spots. Gray dots represent the 
spot counts in cells prior to IFN treatment (dashed mean and best-fit lines included), 
whereas red dots are data points that result post-IFN treatment (solid mean and best-fit line). 
Prior to IFN stimulation, infected cells showed no positive correlation between ISG mRNA 
expression and HCV positive strand spots for either ISG (EIF2AK2, p > 0.05; ISG15, p > 
0.05), as determined by an F test on linear regression parameters. However, a strong positive 
correlation between both ISG mRNA and HCV positive strand spots was observed 
(EIF2AK2, p < 0.0001; ISG15, p < 0.0001) after IFN treatment, as determined by an F test 
on linear regression parameters.
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